<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126450</url>
  </required_header>
  <id_info>
    <org_study_id>CASE8208</org_study_id>
    <secondary_id>NCI-2010-01202</secondary_id>
    <secondary_id>CASE8208</secondary_id>
    <nct_id>NCT01126450</nct_id>
  </id_info>
  <brief_title>Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I, Open-Label Study To Determine The Maximum Tolerated Dose (Mtd) Of The Combination Of Lenalidomide And Cetuximab, And To Evaluate The Efficacy Of This Combination In Subjects With Wild Type K-Ras Metastatic Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the&#xD;
      tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.&#xD;
      Some block the ability of tumor cells to grow and spread. Others find tumor cells and help&#xD;
      kill them or carry tumor-killing substances to them. Giving lenalidomide together with&#xD;
      cetuximab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when&#xD;
      given together with cetuximab in treating patients with metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To further explore the safety and efficacy profile.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      This is a dose-escalation study of lenalidomide.&#xD;
&#xD;
      Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over&#xD;
      1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual,loss of funding and results from EU study showing drug ineffective.&#xD;
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety / Tolerability (type, frequency, severity, and relationship of adverse events to study drug)</measure>
    <time_frame>Courses repeat every 28 days in the absence of unacceptable toxicity.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression of disease</measure>
    <time_frame>Courses repeat every 28 days in the absence of disease progression .</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response according to RECIST</measure>
    <time_frame>at the end of Cycle 2 and every 56 days thereafter until tumor progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab correlatives (FCGRIIa and FCGRIIIa polymorphisms, K-Ras and B-Raf mutations)</measure>
    <time_frame>Tissue collection less than or equal to 28 days prior to day 1 of therapy</time_frame>
    <description>FCGR2a and FCGR3a polymorphisms, K-Ras and B-Raf mutations in patient specimens (paraffin embedded formaldehyde fixed tissues) will be identified.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over 1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>IMiD-1</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Anti-EGFR Monoclonal Antibody</other_name>
    <other_name>C225</other_name>
    <other_name>C225 monoclonal antibody</other_name>
    <other_name>IMC-C225</other_name>
    <other_name>MOAB C225</other_name>
    <other_name>monoclonal antibody C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          -  Wild type metastatic colorectal cancer that failed (progressed, refused or not&#xD;
             tolerated) on at least two treatment regimens including a fluoropyrimidine,&#xD;
             oxaliplatin and irinotecan with or without bevacizumab&#xD;
&#xD;
          -  At least 28 days must have lapsed since completion of prior chemotherapy&#xD;
&#xD;
          -  Subjects must understand and voluntarily sign an informed consent document&#xD;
&#xD;
          -  Subjects must be able to adhere to the study visit schedule and other protocol&#xD;
             requirements&#xD;
&#xD;
          -  Histological or cytological diagnosis of colorectal carcinoma&#xD;
&#xD;
          -  Radiographic or clinical evidence of a measurable disease (by RECIST criteria)&#xD;
&#xD;
          -  Subjects must have received prior treatment with at least 2 prior regimens of therapy&#xD;
&#xD;
          -  ECOG performance status of =&lt; 1&#xD;
&#xD;
          -  Anticipated survival &gt;= 3 months&#xD;
&#xD;
          -  Must agree to also take low dose aspirin (or other anticoagulation if unable to take&#xD;
             ASA) while receiving study drug and for 30 days after study drug is discontinued&#xD;
&#xD;
          -  Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy&#xD;
             test within 10-14 days prior to and again within 24 hours of starting lenalidomide and&#xD;
             must either commit to continued abstinence from heterosexual intercourse or begin TWO&#xD;
             acceptable methods of birth control, one highly effective method and one additional&#xD;
             effective method AT THE SAME TIME, at least 28 days before she starts taking&#xD;
             lenalidomide; FCBP must also agree to ongoing pregnancy testing&#xD;
&#xD;
          -  Men must agree to use a latex condom during sexual contact with a FCBP even if they&#xD;
             have had a successful vasectomy&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  CrCl &lt; 50 mL/min by Cock-Croft and Gault&#xD;
&#xD;
          -  Any serious medical condition or psychiatric illness that places the subject at an&#xD;
             unacceptable risk for study participation or would prevent the subject from signing&#xD;
             the informed consent&#xD;
&#xD;
          -  Use of any cytotoxic chemotherapy within 28 days of study Day 1&#xD;
&#xD;
          -  Use of therapeutic radiation =&lt; 14 days prior to study Day 1&#xD;
&#xD;
          -  Use of thalidomide, or structurally related compounds or biologic response modifier&#xD;
             therapy within 14 days of study Day 1&#xD;
&#xD;
          -  Prior desquamating rash while taking thalidomide, or structurally related compound&#xD;
             therapy&#xD;
&#xD;
          -  Prior &gt;= Grade 2 allergic reaction to thalidomide or structurally related compounds&#xD;
&#xD;
          -  Any prior use of Lenalidomide&#xD;
&#xD;
          -  Subjects may have received prior thalidomide&#xD;
&#xD;
          -  Known or suspected brain metastases&#xD;
&#xD;
          -  Concurrent use or anticipated use of any other anti-cancer agents (except for stable&#xD;
             dose steroid use for control of metastases symptoms) during participation in this&#xD;
             study&#xD;
&#xD;
          -  Absolute Neutrophil Count =&lt; 1500/mm^3 (or 1.5 X10^9/L)&#xD;
&#xD;
          -  Platelet Count =&lt; 100,000/mm^3 (or 100 X 10^9/L)&#xD;
&#xD;
          -  Hemoglobin &lt; 8.0 g/dL&#xD;
&#xD;
          -  Total Bilirubin &gt; 2.0mg/dL&#xD;
&#xD;
          -  Alanine Aminotransferase (ALT/SGPT) &gt;= 3 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate Aminotransferase (AST/SGOT) &gt;= 3 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Peripheral neuropathy &gt;= Grade 2&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Subjects with an infection that is amenable to curative treatment may be eligible for&#xD;
             screening once the infection has been treated, cured and not recurred for at least 14&#xD;
             days&#xD;
&#xD;
          -  Uncontrolled hyper- or hypo- calcemia, glycosemia or thyroidism&#xD;
&#xD;
          -  Arterial or venous thrombotic event in the preceding six months&#xD;
&#xD;
          -  Known history of HIV infection&#xD;
&#xD;
          -  Active viral hepatitis who is on active treatment&#xD;
&#xD;
          -  No other malignancies, other than previously treated non-melanoma skin cancer or&#xD;
             carcinoma insitu of the cervix or breast&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>May 18, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>March 16, 2012</last_update_submitted>
  <last_update_submitted_qc>March 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

